Scot Harper Ph.D.
Vice President of Clinical Operations
Scot L. Harper, Ph.D., was named as vice president of clinical operations in May 2013. He joins the company from PAREXEL International where he was the global portfolio director for oncology, overseeing clinical activities for oncology drugs ranging from Phase 1 to Phase 4 of development. Prior to this, he was the vice president of Novartis’ North American clinical operations, where he managed clinical operations of all stages of development, including products such as Gleevec, Tasigna and Diovan. Before this, he was at Eli Lilly and Company, where he held a variety of senior roles, most recently senior director of clinical operations, which included oversight of clinical trials in areas including oncology, neuroscience, diabetes and men’s health. Dr. Harper began his career at SmithKline Beecham, where he worked in new product development. Dr. Harper holds a B.S. degree in zoology from DePauw University, a master’s degree in physiology from Indiana University School of Medicine, a master’s degree in business from the University of South Alabama, and a Ph.D. in cardiovascular physiology from Indiana University School of Medicine.